User
Favorite list
As a global market leader with numerous subsidiaries and distributors, Miltenyi Biotec is committed to providing our customers around the world with the highest quality products. In addition to direct selling in more than 20 countries in North America, Europe and Asia/Pacific, Miltenyi Biotec also provides support for our customers through an extensive distributor network covering dozens of additional countries.
Immuno-oncology research focuses on innovative approaches that exploit the immune system for cancer therapy by targeting cellular or molecular structures to prevent tumor immune evasion.
As an innovative biotechnology company, we at Miltenyi Biotec offer cutting-edge technologies and high-quality products to support your immuno-oncology research.
Whether you are interested in studying immune cells or cancer cells from the tumor microenvironment, or cellular models for the validation of novel immunotherapeutic agents – check out our application pages for the respective cell types (engineered T cells for research, monocytes and Mo-DCs, NK cells, tumor-infiltrating leukocytes (TILs)) to find relevant application data and protocols based on our immuno-oncology products.
For example, download our scientific poster on the right, to learn about our automated TIL isolation and analysis workflow.
Moreover, we offer clinical-scale immuno-oncology products for an easy transition of your research workflows into the clinic (engineered T cells, dendritic cells for immunotherapy, regulatory T cells for immunotherapy, T cell depletion in graft engineering).
Do you, for example, know our T cell transduction process depicted in the figure below?
Related PDFs:
Generation of functional CAR T cells from CD4+ and CD8+ T cells (Application note)
Generation of functional CAR T cells from pan T cells isolated by MACS® technology (Application note)
MACS® Technology facilitates mixed lymphocyte reaction (Application note)
Antigen-specific restimulation of CD8+ T cells by cross-presenting dendritic cells (Application note)
Allogenic T cell infusion alters iron regulatory gene expression (customer protocol)
Adoptive transfer of pan T cells separated with MACS® Technology (customer protocol)
Are you new to the immuno-oncology field or an experienced researcher, ready to tell your success story? Check out our immuno-oncology activities to find relevant webinars, talks, meetings, or the opportunity to win a travel award to selected meetings and the chance to share your research insights with the scientific community.
Click on the link below to explore
immuno-oncology activities supported by Miltenyi Biotec
Copyright © 2020 Miltenyi Biotec and/or its affiliates. All rights reserved.
View details
Download PDF
